Germany

Apogenix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

Lead Product(s): Asunercept

Therapeutic Area: Infections and Infectious Diseases Product Name: APG101

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 28, 2020

Details:

The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.

Atriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Publication in PNAS Unveils Molecular Pathway Required for Influenza Virus Replication with Large Potential as an Antiviral Drug Target

Lead Product(s): ATR-002

Therapeutic Area: Infections and Infectious Diseases Product Name: ATR-002

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

ATR-002 is an oral small molecule, in a dose escalation study demonstrated excellent safety and tolerability and the observed pharmacokinetic profile supports the intended once-daily regime for the upcoming Phase II clinical development.

AiCuris

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AiCuris Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir to Treat HSV Infections in Immunocompromised Patients

Lead Product(s): Pritelivir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 05, 2020

Details:

Receiving Breakthrough Therapy Designation will facilitate AiCuris goal of bringing pritelivir to patients as quickly as possible . Company is now preparing to add a pivotal Phase 3 trial part to the ongoing Phase 2 study in immunocompromised patients.

CordenPharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Moderna Extends Lipid Supply For Coronavirus Vaccine

Lead Product(s): mRNA-1273

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Moderna Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 28, 2020

Details:

The amended agreement now includes CordenPharma Chenôve (FR) and CordenPharma Colorado (US) for the manufacture of larger-scale volumes of lipids, while continuing to draw upon CordenPharma Switzerland’s long-standing reputation as a leader in specialized lipid manufacturing.

Atriva Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

Lead Product(s): ATR-002

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Atriva’s lead product ATR-002 candidate is the only host-targeted antiviral specifically developed to treat respiratory infections with RNA viruses, such as influenza virus and the novel SARS-CoV-2.

Adrenomed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock

Lead Product(s): Adrecizumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 21, 2020

Details:

The study achieved its primary endpoint: Adrecizumab demonstrated a favorable safety profile and was well tolerated.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Apogenix

Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

Atriva Therapeutics

Publication in PNAS Unveils Molecular Pathway Required for Influenza Virus Replication with Large Potential as an Antiviral Drug Target

AiCuris

AiCuris Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir to Treat HSV Infections in Immunocompromised Patients

CordenPharma

Moderna Extends Lipid Supply For Coronavirus Vaccine

Atriva Therapeutics

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

Adrenomed

Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock